{"id":"W2947126667","doi":"10.1136/annrheumdis-2019-eular.2325","title":"THU0117 PHARMACOKINETICS AND SHORT-TERM SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Pfizer Japan; AbbVie Canada; Astellas Foundation for Research on Metabolic Disorders; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; AstraZeneca; Teijin Pharma; Pfizer; Japan Blood Products Organization; Ono Pharmaceutical","keywords":"Medicine; Pharmacokinetics; Janus kinase inhibitor; Term (time); Pharmacology; Internal medicine; Janus kinase","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004208064,0.0003150026,0.000669212,0.0002003605,0.0001931684,0.0005730608,0.0001821864,0.0004278571,0.00172808],"category_scores_gemma":[0.0009302027,0.0002251337,0.0005722358,0.0002123032,0.0002823944,0.000510256,0.0001342847,0.00097443,0.0003922328],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005390121,"about_ca_system_score_gemma":0.0003753248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001534918,"about_ca_topic_score_gemma":0.001976427,"domain_scores_codex":[0.9997842,0.00007196327,0.0000145767,0.00004613184,0.00003269437,0.00005050064],"domain_scores_gemma":[0.9996756,0.00007637903,0.0001001649,0.00003086618,0.00002764764,0.00008922275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.596825,0.00463316,0.1190601,0.0004565425,0.002097434,0.0007347098,0.000314362,0.002702389,0.1232367,0.0004380087,0.003240797,0.1462608],"study_design_scores_gemma":[0.02386836,0.1147919,0.8164355,0.00008707459,0.002654006,0.001873595,0.0004060364,0.008333849,0.02443421,0.000482983,0.006466867,0.0001656369],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970704,0.001357459,0.0002182877,0.00007822154,0.00001953447,0.00002470338,0.0003820065,0.00003067497,0.0008186836],"genre_scores_gemma":[0.99836,0.0002313733,0.00008636517,0.0000787654,0.00002175789,0.00001783754,0.000418215,0.000006486382,0.0007791794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00172808,"threshold_uncertainty_score":0.005781054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01826281367615477,"score_gpt":0.2858025213910009,"score_spread":0.2675397077148461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}